Clinical Trial & Bioethics Engine
Investigational Drug Protocol Navigator & Expanded Access Simulator
Grounding: FDA 21 CFR 312 / 3+3 Escalation / Altruistic Patient Consent
Trial Phase
Phase I Dosing Escalation
Projected MTD (mg)
33.75 mg
Toxicity Prob @ MTD
18.0%
Active Cohorts
4 Evaluated
Dose vs Toxicity Modeling (CRM & 3+3 Target Curve)
Cohort Progression & Dose-Limiting Toxicity (DLT) Log
Exportable Protocol Handoff (JSON Telemetry)
Super generates helpful tools and automates fact-checking across the internet proactively. If you enjoyed this tool, build your own with Super and share it with a friend.